Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.32 EPS, down 509.38% or $1.63 from last year’s $1.31 per share.

At the moment 4 analysts are watching Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), 1 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 4 analysts have a mean sales target of 45.51 million. For the quarter ending Sep-16, 4 analysts have a mean sales target of 62.06 million whilst for the year ending Dec-16, 4 analysts have a mean target of 206.54 million.

In terms of earnings per share, 4 analysts have a 1.08 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a 1.24 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of 4.12 EPS.

The biggest institutional shareholders in Eagle Pharmaceuticals, Inc. include ProQuest Associates IV LLC which owns 5 million shares in the company valued at $423.86 million. Consonance Capital Management LP is the second biggest holder with 1 million shares currently valued at 124.68 million whilst Janus Capital Management LLC has 1 million shares valued at 108.94 million.

Total shares held by institutions as of the most recent company filings are 15,926,568 with a reported 949,820 bought and 1,032,141 sold. These holdings make up 95.81% of the company’s outstanding shares.

Currently insiders hold 1,436,459 shares in the business which makes up 9.19% of shares. The biggest holder currently is Scott L. Tarriff who owns 1,369,946 shares (8.76% of those outstanding), whilst Mr. Steven B. Ratoff holds 19,374 (0.12% of shares outstanding) and Sander A. Flaum holds 16,374 (0.10% of shares outstanding).

The stock decreased 1.41% or $0.51 during the last trading session, hitting $60.00. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has fallen 27.3% over the past 6 months and is downtrending.